D.Western Therapeutics Institute, Inc.

As of June 30, 2026, D.Western Therapeutics Institute, Inc. carries a market capitalization of 4.25B, placing it among publicly traded companies globally. Its enterprise value stands at 3.25B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

D.Western Therapeutics Institute, Inc.'s next confirmed earnings release is scheduled for November 12, 2026.

As of June 30, 2026, D.Western Therapeutics Institute, Inc. has 57.47M shares outstanding.

These figures are as of June 30, 2026.

As of June 30, 2026, D.Western Therapeutics Institute, Inc. maintains a current ratio of 10.13, meaning it holds 10.1x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended June 30, 2026.

As of the close on October 22, 2026, D.Western Therapeutics Institute, Inc.'s stock has declined approximately 40.37% over the past 52 weeks. The 50-day moving average sits at 78.28, while the 200-day moving average is 86.13.

As of June 30, 2026, D.Western Therapeutics Institute, Inc. holds 1.58B in cash and equivalents against 583.15M in total debt, resulting in a net debt position of -998.38M. Total book value stands at 1.41B, with working capital of 1.71B providing operational flexibility.